Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada Implements New Recall/Disclosure Policy

This article was originally published in The Pink Sheet Daily

Executive Summary

Health Canada finalizes guideline on its new powers to order recalls or disclose information related to serious risks of injuries for drugs, but says it will develop more details on how it will use the authorities.

You may also be interested in...



U.K. Use Of J&J's Cisapride Halted Pending 2001 Ruling On Status In EU

The U.K.' s Medicines Control Agency is withdrawing Johnson & Johnson's cisapride from the market, pending a decision on the drug's status in the EU, expected in 2001.

AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug

Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include five new products, including Lumoxiti, AstraZeneca's drug for hairy cell leukemia. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel